Analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a report released on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Down 3.2 %
Shares of NASDAQ:PULM opened at $2.13 on Friday. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.75. The company’s fifty day simple moving average is $2.07 and its 200 day simple moving average is $2.03. The firm has a market cap of $7.77 million, a price-to-earnings ratio of -0.72 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The company had revenue of $1.55 million for the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- Compound Interest and Why It Matters When Investing
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- How to buy stock: A step-by-step guide for beginnersÂ
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Stock Dividend Cuts Happen Are You Ready?
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
